<bill session="117" type="s" number="4390" updated="2022-12-29T17:48:36Z">
  <state datetime="2022-06-14">REFERRED</state>
  <status>
    <introduced datetime="2022-06-14"/>
  </status>
  <introduced datetime="2022-06-14"/>
  <titles>
    <title type="display">Accelerated Approval Transparency Act</title>
    <title type="short" as="introduced">Accelerated Approval Transparency Act</title>
    <title type="official" as="introduced">A bill to require summary approval information with respect to certain approved drugs and biological products.</title>
  </titles>
  <sponsor bioguide_id="H000273"/>
  <cosponsors/>
  <actions>
    <action datetime="2022-06-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-06-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-21T20:35:57Z" status="Introduced in Senate">Accelerated Approval Transparency Act

This bill requires the Food and Drug Administration to include a summary of the reasons a drug or biologic received accelerated approval to treat a serious or life-threatening disease or condition in the public action package for the drug or biologic.</summary>
</bill>
